Funding Opportunities

• Minor Use Minor Species Development of Drugs (R01)
  (PAR-18-827)
  Food and Drug Administration
  Application Receipt Date(s): August 27, 2018; January 18, 2019; August 16, 2019; January 17, 2020; August 14, 2020; January 15, 2021 by 11:59 PM Eastern Time Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
• NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
  (PAR-18-828)
  National Center for Complementary and Integrative Health
  Office of Dietary Supplements
  Application Receipt Date(s): New Applications: August 31, 2018; February 7, 2019; and October 8, 2019by 5:00 PM local time of applicant organization. Resubmission Applications: September 7, 2018; February 21, 2019; and October 22, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
  (PAR-18-829)
  National Center for Complementary and Integrative Health
  Office of Dietary Supplements
  Application Receipt Date(s): New Applications: August 31, 2018; February 7, 2019; and October 8, 2019by 5:00 PM local time of applicant organization. Resubmission Applications: September 7, 2018; February 21, 2019; and October 22, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)
  (PAR-18-830)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Cancer Institute
  National Eye Institute
  Application Receipt Date(s): November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• The Role of Epitranscriptomics in Development and Disease (R21 - Clinical Trial Not Allowed)
  (PAR-18-831)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): November 7, 2018, June 3, 2019, March 3, 2020, November 7, 2020, June 3, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
  (PAR-18-832)
  National Institute of Mental Health
  Application Receipt Date(s): September 11, 2018, September 11, 2019, September 11, 2020, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
  (PAR-18-833)
  National Institute of Mental Health
  Application Receipt Date(s): September 11, 2018, September 11, 2019, September 11, 2020, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Sustained Release Innovation for HIV (SRI) (R61/R33 Clinical Trial Optional)
  (RFA-AI-18-006)
  National Institute of Allergy and Infectious Diseases
  National Institute of Mental Health
  Application Receipt Date(s): November 30, 2018, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on this date.
• Immune Mechanisms at the Maternal-Fetal Interface (R01 Clinical Trial Optional)
  (RFA-AI-18-023)
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): October 4, 2018 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)
  (RFA-CA-18-015)
  National Cancer Institute
  Application Receipt Date(s): August 31, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this FOA. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required)
  (RFA-CA-18-016)
  National Cancer Institute
  Application Receipt Date(s): August 31, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites (UG1 Clinical Trial Required)
  (RFA-CA-18-017)
  National Cancer Institute
  Application Receipt Date(s): August 31, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Gastrointestinal Mechanisms Contributing to HIV Pathogenesis (R01 Clinical Trial Not Allowed)
  (RFA-DK-18-009)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 14, 2019, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates.
• Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)
  (RFA-HD-19-015)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): November 6, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Large Animal Testing Centers for Evaluation of Somatic Cell Genome Editing Tools (U42 - Clinical Trial Not Allowed)
  (RFA-RM-18-014)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): August 24, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.